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RNA interference (RNAi) is a widely used method for analysis of
gene function in tissue culture cells. However, to date there has
been no reliable method for testing the specificity of any particular
RNAi experiment. The ideal experiment is to rescue the phenotype
by expression of the target gene in a form refractory to RNAi. The
transgene should be expressed at physiological levels and with its
different splice variants. Here, we demonstrate that expression of
murine bacterial artificial chromosomes in human cells provides a
reliable method to create RNAi-resistant transgenes. This strategy
should be applicable to all eukaryotes and should therefore be a
standard technology for confirming the specificity of RNAi. We
show that this technique can be extended to allow the creation of
tagged transgenes, expressed at physiological levels, for the fur-
ther study of gene function.
off-target effects  loss-of-function experiment  interferon response 
gene knockdown
RNA interference (RNAi) has become a widely used tool forfunctional genomic studies in vertebrates and invertebrates
(1). RNAi works by silencing a gene through homologous short
interfering dsRNAs (siRNAs), which trigger the destruction of
corresponding mRNA by the RNA-induced silencing complex
(RISC) (2). The ease, speed, and cost-effectiveness have made
it the method of choice for loss-of-gene function studies. How-
ever, RNAi has produced a new set of problems in determining
the specificity of the altered phenotype. Recent publications
reported off-target effects that in addition to the targeted genes
led to changes in the expression of other genes on both mRNA
and protein level (3–5). Also, several authors reported the
induction of genes involved in the IFN response machinery
(6–9), further challenging the reliability of RNAi in loss-of-
function studies.
Control experiments are therefore important to confirm the
specificity of an RNAi phenotype (10). The ultimate way to be
sure of the specificity of a loss-of-function phenotype is a rescue
experiment (11). To perform such an experiment in mammalian
cells, the reintroduced gene must be resistant to the trigger
dsRNA. Ideally, this rescue gene should also be expressed within
the physiological range. For other important model organisms
such as yeast, rescue experiments can be easily achieved by using
homologous recombination, thereby ensuring physiological ex-
pression of the rescue construct. The lack of efficient homolo-
gous recombination in mammalian cells makes this approach
unpractical in this experimental system.
One approach to generate an RNAi-resistant construct is to
create silent point mutations in the target site of the coding
sequence or to target a sequence in the 3UTRof a cDNA, which
is replaced in the rescue construct (12). Although this approach
can work to achieve rescue of an RNAi phenotype, it has certain
limitations (Table 1). First, this approach requires the availabil-
ity of full-length high-quality cDNAs, and, although the list of
full-length cDNA clones is growing, a clone may not be available
for any given gene. Second, the cloning procedure to introduce
a point mutation in the coding sequence or the replacement of
the 3UTR is time consuming and expensive, especially for large
transcripts. This shortcoming may be avoided by using a cross-
species cDNA construct. Third, cDNAs do not allow the expres-
sion of alternatively spliced transcripts. Fourth, expression from
vectors carrying cDNA inserts depends on the promoter used to
drive the transgene expression. Most of these promoters are
derived from viral or model vertebrate promoters that do not
recapitulate physiological expression of most transgenes. This
point may be critical for many rescue experiments, because
inappropriate expression levels of a particular protein would
either not rescue or could cause artifactual effects (10). Thus, a
cDNA-based approach is not generally applicable and reliable
for RNAi rescue experiments.
We propose a technology circumventing the problem of
inefficient homologous recombination in mammalian cells by
expressing an orthologous gene from a closely related species,
including its regulatory sequences carried on a bacterial artificial
chromosome (BAC). In contrast to cDNA expression constructs,
the transfer of these large segments of genomic DNA speeds up
the generation of transgenic cell lines and allows physiological
expression and the generation of alternatively spliced variants of
the transgene. Mouse geneticists have successfully used these
advantages of large constructs for the generation of transgenic
animals. For many years, cDNA constructs have been used to
generate transgenic mice. Because of position effects, many
founder lines needed to be tested to identify one with the
appropriate expression pattern. The development of BAC tech-
nology for generation of transgenic mice has alleviated this
problem to a large extent. Coupled with the development of
methodology to specifically mutate large DNA molecules (13),
now termed recombineering (14, 15), BACs are now the pre-
ferred choice to generate transgenic animals (16, 17).
Here, we establish BACs as rescue constructs for RNAi in
mammalian tissue culture cells. The use of BACs carrying the
orthologous gene from a closely related species confers RNAi
resistance to the transgene. The cross-species strategy also
abolishes the need for introducing point mutations or replacing
the 3UTR. We establish this approach for human tissue culture
cells by the use of mouse BACs. This experimental concept
provides a standardized platform to check the specificity of any
particular RNAi experiment. In addition, this technology mimics
homologous recombination by depleting an endogenous gene by
means of RNAi and replacing it with a transgene while main-
taining normal gene expression. Therefore, our approach helps
to turn mammalian tissue culture cells into a real genetic system
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that should be useful for protein localization studies, structure
function analyses, and the purification of protein complexes.
Methods
BAC Engineering. The BACs RP23-285E19 [harboring mouse
SNW1 (mSNW1)], RP24-181C3A [harboring mouse DNAJA3
(mDNAJA3)], and RP24-351L1 [harboring mouse SPD2
(mSPD2)] were obtained from the BACPAC Resources Center
(http:bacpac.chori.org). NeoKanr-dsRed and EGFP-IRES-
Neo cassettes were PCR amplified with primers carrying 50
nucleotides of homology to the targeting sequence. Recom-
bineering of the BACs was performed as described (18) (Gene
Bridges, Dresden, Germany).
BAC Transfection.HeLa cells were seeded 16 h before transfection
into 6-cm dishes with a density of 700,000 cells per well in 5 ml
of medium (DMEM10% FBS2 mM glutamine100 units/ml
penicillin100 g/ml streptomycin). Transfection was performed
with Effectene (Qiagen, Valencia, CA) by using 1 g of super-
coiled BACDNA, purified with the large-construct kit (Qiagen).
The cells were transferred 24 h later on 10-cm dishes and
cultivated in selection medium containing 750 gml geneticin
(GIBCO).
Detection of DNAJA3 and SNW1 Expression. RNA was extracted
from transgenic HeLa cells by using the RNeasy Mini Kit
(Qiagen). cDNA was synthesized with SuperScript II reverse
transcriptase (Invitrogen), and expression of the transgenes was
detected by PCR by using the primers 5-AGTCACCCACA-
CAAGCACTG-35-AAGCTGTAAGCCGGGTCTTT-3
(DNAJA3) and 5-TGACCAAAGGCTCTTCAACC-35-
CTGGACAAGGACATGTATGGTG-3 (SNW1). The SNW1
PCR product was digested with SfaNI (New England Biolabs),
and products were separated on a 3% agarose gel.
Endoribonuclease-Prepared siRNA (esiRNA) Synthesis.We generated
esiRNA against a 3 UTR fragment from human SNW1
(hSNW1) tagged with T7 promoter sequences on both sides (Fig.
5, which is published as supporting information on the PNAS
web site). The template for in vitro transcription of firefly
luciferase was generated as described elsewhere (19). EsiRNA
was synthesized as described (20) with a modified purification
procedure (21).
Quantification of hSNW1 Knockdown. WT HeLa cells and cells
expressing mSNW1 were seeded 16 h before transfection into
12-well plates with a density of 20,000 cells per well in 1 ml of
medium (DMEM10% FBS2 mM glutamine100 units/ml pen-
icillin100 g/ml streptomycin). Transfection was performed
with Oligofectamine (Invitrogen) by using 0.5 g of esiRNA
targeting hSNW1 or firefly luciferase. Cells were harvested 48 h
after transfection, and RNA extraction and cDNA synthesis were
performed as described above.
hSNW1mRNA expression was quantified by quantitative PCR
by using the Brilliant SYBR Green system and the Mx4000
Multiplex Quantitative PCR system (Stratagene), by using the
primers 5-TCCTAATCCTCGGACTTCCA-35-GGGC-
CATATCTTTACCACCTC-3. Expression levels of hSNW1 in
cells transfected with hSNW1-specific esiRNA were normalized
against the expression level of cells transfected with esiRNA
targeting firefly luciferase.
Rescue Experiment. WT HeLa cells and cells expressing mSNW1
or mSPD2 were seeded 16 h before transfection into 96-well
plates with a density of 2,000 cells per well in 100 l of medium.
Transfections were performed by using 50 ng of esiRNA
(hSNW1), or 40 nM siRNA (hSPD2) and Oligofectamine (In-
vitrogen). The sequences of the hSPD2 siRNA (Ambion, Austin,
TX) are 5GGAAGACAUUUUCAUCUCUtt-3 and
5AGAGAUGAAAAUGUCUUCCtt-3. Because of three mis-
matches to this sequence, themouse transcript is not significantly
silenced by this siRNA.
Cell viability was measured 96 h after transfection by using the
WST-1 assay (Roche Diagnostics). Mitotic cells were counted
36 h posttransfection.
For visualization of the mitotic spindles, HeLa cells grown on
coverslips were transfected as described above. Forty-eight hours
after transfection, the cells were fixed and permeabilized in
Fig. 1. Experimental strategy of RNAi rescue by BAC transgenesis. RFP, red fluorescent protein; Kanneor, kanamycinneomycin resistance gene; Cmr,
chloramphenicol resistance gene; ori, origin of replication; BB, BAC backbone; CSI-BAC, cross-species RNAi rescue-BAC.
Table 1. Comparison of the cDNA and transgenic BAC approaches for generation of RNAi rescue constructs
Method Modification of full-length cDNA clone inserts Use of transgenic BACs
Availability of rescue constructs Limited number of full-length ORF cDNAs High Bac coverage of the mousehuman genome
Expression level Dependent on artificial promoter Dependent on natural promoter
Often not physiological Physiological range
Transcriptional regulation No Yes
Alternative splicing No Yes








methanol at 20°C for 8 min. Cells were washed with PBS and
incubated 10 min in PBS containing 0.2% fish skin gelatin
(Sigma). Cells were incubated for 20 min with a mouse mono-
clonal antibody against tubulin (DM1, Sigma) either directly
labeled with FITC or using a donkey anti-mouse antibody
labeled with Texas red and mounted in the presence of DAPI (1
gml1) to visualize chromatin. Three-dimensional data sets
were acquired on a DeltaVision imaging system (Applied Pre-
cision, Issaquah,WA) equipped with an Olympus (Melville, NY)
IX70 microscope. Images were computationally deconvolved by
using the SOFTWORX software package and shown as two-
dimensional projections.
Results and Discussion
Generation of Transgenic Human Cell Lines. The mouse genome-
sequencing project has produced overlapping large genomic
constructs, including libraries of BACs. These constructs are
typically larger than 100 kb, and most genes are available on a
single BAC. Therefore, these constructs are well suited to
express genes within their physiologically genetic ‘‘environ-
ment.’’ The proportion of human genes without any homologue
currently detectable in the mouse genome is 1% (22). There-
fore, the described methodology should be generally applicable
to almost all human genes. Based on the BAC coverage and gene
size in mouse, we estimate that BACs containing the genomic
sequence of a gene and 20 kb of upstream sequence should be
available for 90% of all genes. These BACs are available
through several public resources and can be rapidly identified
with open-access databases.
To allow rapid assessment of transfection efficiency and
selection for stable integration of themouse BAC in human cells,
we designed a universal cassette carrying a neomycinkanamycin
selection marker and a red fluorescent protein (RFP) marker
that carries homologous sequences to replace the chloramphen-
icol cassette on the BAC backbone by recombineering (14, 15).
The incorporation of this cassette replaces the internal chlor-
amphenicol resistance gene, thereby allowing a simple selection
scheme to obtain successfully modified BACs, monitoring kana-
mycin resistance and chloramphenicol sensitivity (Fig. 1). All
positive colonies analyzed had integrated the cassette at the
intended locus, demonstrating the efficiency and simplicity of
this approach. By using the universal cassette, the BAC modi-
fication can be streamlined and performed within 2 days,
allowing rapid processing of many different BACs.
The large size of BAC constructs makes them more difficult
to transfect into mammalian cells than cDNA constructs. To
monitor and optimize the transfection efficiency, we included
the RFP gene in the replacement cassette. Based on the expres-
sion of RFP monitored 48 h after transfection, we obtained an
average transfection efficiency of2%with standard lipofection
reagents, which was sufficient to obtain many clones that stably
express the transgene (Fig. 6, which is published as supporting
information on the PNAS web site).
We modified two BACs carrying the mouse orthologues of the
two human genes SNW1 and DNAJA3. SNW1 is a transcription
coactivator and pre-mRNA splicing factor (23) that we identified
recently to be essential for cell division in human cells by a large
scale RNAi screen (21). We showed that RNAi-mediated de-
pletion of SNW1 in HeLa cells resulted in spindle and cytokinesis
defects, suggesting a link between splicing and cell division. To
test the specificity of this provocative knockdown phenotype, we
generated a BAC transgenic cell line that expresses the mouse
SNW1 gene. To test for alternative splicing of a murine gene in
human cells, we chose the mouse orthologue of the human gene
DNAJA3, a heat shock protein for which alternatively spliced
transcripts have been reported (24).
Alternative Splicing and Physiological Expression of Murine Trans-
genes in Human Cells. To test whether alternative splicing of the
murine DNAJA3 gene (mDNAJA3) would take place in human
HeLa cells, we designed a primer pair specific for two isoforms,
which should generate two PCR fragments of different length.
RT-PCR using cDNA derived from HeLa cells that have stably
integrated a BAC carryingmDNAJA3 revealed the expression of
two products with the expected length for both splice isoforms,
indicating successful alternative splicing of murine genes in
human cells (Fig. 2a).
To analyze and compare the expression levels of an endoge-
nous human gene with the mouse transgene in human cells, we
developed a PCR-based assay for SNW1. We chose a single
primer pair that perfectly matches to both human (hSNW1) and
Fig. 2. Expression and RNAi resistance ofmouse transgenes. (a) Detection of
expression and alternative splicing of mDNAJA3 by RT-PCR. Lane 1, the two
bands (495-bp and 377-bp) amplified from cDNAofHeLa cells transfected and
selected for a BAC carrying mDNAJA3 representing the two splice isoforms;
lane 2, negative control (cDNA from WT HeLa cells); lane 3, non-template
control. M, marker. (b) Expression levels of hSNW1 andmSNW1 in transgenic
cells. The comparison of the band intensities indicates relative expression
levels of hSNW1 and mSNW1. Lane 1, undigested 161-bp fragment from the
same clonedepicted in lane 2; lanes 2–11, SfaNI digestionproducts of a 161-bp
fragment amplified from cDNA of 10 clones from HeLa cells transfected and
selected for a BAC carrying mSNW1 (the upper band represents the uncut
human-specific fragment, the lower band the mouse-specific fragment); lane
12, digested fragment generated from cDNA of WT HeLa cells. M, Marker. (c)
Knockdown of hSNW1 in transgenic HeLa cells. hSNW1 expression after
transfection of esiRNAs targeting hSNW1 andfirefly luciferase. hSNW1mRNA
expression was quantified 2 days after transfection. Expression levels were
normalized against hSNW1 expression of cells transfected with esiRNA tar-
geting firefly luciferase. (d) Expression levels of hSNW1 andmSNW1 in trans-
genic HeLa cells. Lanes 1 and 2, SfaNI digestion products of the 161-bp
fragment amplified from cDNA of transgenic HeLa cells transfected with
esiRNA targeting firefly luciferase (lane 1) and hSNW1 (lane 2) (note the
change of relative band intensities indicating the specific knockdown of
hSNW1); lanes 3 and 4, undigested 161-bp fragment amplified from cDNA of
transgenic HeLa cells transfectedwith esiRNA targetingfirefly luciferase (lane
3) and hSNW1 (lane 2); lane 5, non-template control. M, marker.
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mouse (mSNW1) cDNA. Both the human and the mouse frag-
ments will be amplified proportional to their starting template
number. We used a restriction fragment length polymorphism to
distinguish between the expression from the human gene and the
mouse transgene (Fig. 7, which is published as supporting
information on the PNASweb site). The analysis of 10 transgenic
clones revealed that 9 of 10 clones expressed mSNW1 at almost
identical levels as hSNW1 (Fig. 2b).
Although regulatory elements such as CpG islands may differ
in organization between human andmouse (25), gene expression
patterns are strongly conserved for most genes of both species.
Therefore, we expect that most mouse genes should be expressed
at similar levels as their human orthologues. Also, most alter-
native splicing events are likely to be conserved between mouse
and human (26).
Only very few genes of mouse and human should not be fully
interchangeable, because they are either species-specific or display
significant differences in protein structure and function. Species-
specific gene expression in human and mouse is restricted to some
genes involved in, e.g., immune and xenobiotic response, and for
polymerase I-dependent transcription of rRNAs (27–29). In such
cases, one could alternatively rescue with a BAC carrying the same
gene containing silent mutations or a modified 3 UTR. This
strategy could be realized with the experimental protocols de-
Fig. 3. Rescue experiment. (a–d) Phase contrast microscopic images of WT HeLa cells (a and c) and BAC transgenic HeLa cells expressingmSNW1 (b and d) 96 h
after transfectionwith esiRNA targetinghSNW1 (c andd) andfirefly luciferase as negative control (a andb). (e) Effect on cell viability of esiRNA targetinghSNW1.
Cells were assayed 96 h after transfection. Shown is the reduction of cell viability as determined with the WST-1 assay normalized against the negative control
luc (esiRNAdirectedagainstfirefly luciferase). (f–i)WTHeLa cells ( fandh) andBACtransgenicHeLa cells expressingmSNW1 (gand i)were transfectedwithesiRNA
targeting hSNW1 (h and i) and firefly luciferase as negative control ( f and g) and imaged by 3D deconvolution microscopy 48 h after transfection for tubulin
(green) and DNA (blue). [Scale bars: 100 m (a–d) and 5 m ( f–i).] (j) Frequency of aberrant spindles. We counted the frequency of aberrant spindles 48 h after
transfection for 50 mitotic cells per coverslip. Error bars represent the standard variation. mSNW1-BAC, HeLa cells that have stably integrated the BAC carrying
mSNW1; luc, esiRNA targeting firefly luciferase; hSNW1, esiRNA targeting hSNW1.








scribed here and would require the generation of a specific con-
struct for the recombineering step. This strategy would be more
time-consuming than the described modification of the BAC back-
bone but would still allow physiological expression and alternative
splicing of the gene of interest, and therefore would be preferable
over a cDNA rescue approach.
Knockdown Specificity in Transgenic Cells Lines. To test the human-
specific knockdown of SNW1 in transgenic cells, we generated an
esiRNA (20) targeting a sequence fragment of the 3 UTR of
hSNW1. We tested the silencing efficiency of this esiRNA inWT
HeLa cells by quantitative PCR and found a reduction of 90%
at the mRNA level (Fig. 2c).
To check the specific knockdown of hSNW1 in the transgenic
clones after esiRNA transfection, we analyzed the relative
expression levels after transfection of the human-specific es-
iRNA using the same PCR-restriction fragment length polymor-
phism assay described above. We observed a strong reduction of
the human-specific product compared with the mouse-specific
product (Fig. 2d). These results indicate a specific and efficient
knockdown of the human but not of the murine mRNA.We thus
conclude that a mouse gene expressed from a BAC escapes
RNAi triggered by human-specific siRNAs.
The RNAi resistance of the rescue gene is based on sequence
differences between the transgenic mRNA and the siRNA(s)
perfectly matching the endogenous mRNA. The number of
nucleotide differences between mouse and human transcripts is
in a range, which allows the design of siRNAs silencing only the
human homologues. In particular, the 3 UTR may be useful for
this purpose, because this mRNA region exhibits a lower level of
sequence similarity between mouse and human (average 71%)
compared with coding sequences (average 86.4%) (30). This
aspect may be critical, because imperfectly matching siRNAs can
potentially hit multiple mRNAs based on microhomology at the
5 end of the antisense strand andor inhibit translation in a
microRNA (miRNA)-like manner (31, 32). Because of its high
degree of specificity (21), esiRNA is an excellent source for
running down the endogenous gene while leaving the transgene
expression unchanged. Hence, an independent esiRNA gener-
ated from the coding region of hSNW1 that shares 92% sequence
identity with mSNW1 resulted in a similar reduction of hSNW1
transcripts while not affecting mSNW1 expression (data not
shown).
Rescue of an RNAi Phenotype. Recently, we identified SNW1 as an
indispensable gene for cell division in HeLa cells (21). The
knockdown of SNW1 results in mitotic arrest and cytokinesis
defects followed by apoptosis. To test whether the expression of
the murine orthologue reverts the deleterious effect of the
knockdown phenotype of human SNW1, we transfected esiRNA
targeting hSNW1 into WT and mSNW1 BAC-transgenic HeLa
cells. Transfection of human-specific esiRNA into WT cells
resulted in markedly lower cell density, with many dead cells 96 h
after transfection. In contrast, HeLa cells expressing mSNW1
grew essentially like WT cells transfected with esiRNA targeting
firefly luciferase (Fig. 3 a–e). The analysis of the mitotic spindle
morphology further revealed the reversion of the spindle defect
phenotype in transgenic cells in comparison with WT cells upon
depletion of hSNW1 (Fig. 3 f–j). We conclude that the expression
of the mouse orthologue of a targeted human gene rescues the
RNAi phenotype of SNW1. We have therefore confirmed the
essential function of SNW1 and its cell division phenotype in
HeLa cells.
These data show that cross-species BAC transgenic cell lines
allow easy, quick, and efficient confirmation of RNAi pheno-
types. We demonstrated the proof-of-concept for the human–
mouse system. In principle, this concept should be applicable for
all closely related species among the eukaryotes, which are
subject to RNAi-based functional studies, e.g., Caenorhabditis
elegans–Caenorhabditis briggsae and Drosophila melanogaster–
Drosophila yakuba.
BAC Gene Tagging and RNAi Rescue. In addition to loss-of-function
and gain-of-function analyses, protein localization studies are an
important tool in functional genomics. The use of GFP as a
fusion tag has added great value to protein localization studies
(33). In addition to localizing a protein to a cell compartment,
it also allows us to study the dynamic behavior of a protein in
living cells through the use of time-lapse video microscopy. In
budding yeast, almost all ORFs have been GFP-tagged to
provide a global view on protein localization in this organism
(34). Importantly, in this study, the ORFs were targeted by
means of homologous recombination to allow expression from
their endogenous promoters. Hence, the fusion proteins were
expressed at physiological levels, and, therefore, mislocalization
due to overexpression of proteins was avoided.
In human tissue-culture cells, large scale GFP-tagging
Fig. 4. BAC tagging for functional studies inmammalian cell lines. (a) Diagram illustrating procedures. TAG, fusion sequence to investigate gene function (e.g.,
GFP); IRES, internal ribosome entry site; neo, kanamycinneomycin resistance gene; r, resistance gene of the BAC; BB, BACbackbone. (b) HeLa cell line containing
themouse SPD2 BAC taggedwith GFP stained for DNA (blue), microtubules (red), andGFP (green). Note the presence ofmSPD2-GFP on both poles of themitotic
spindle. (c) WT HeLa cells or HeLa cells stably expressing themSPD2 BAC tagged with GFP submitted to hSPD2 RNAi. Error bars represent the standard variation.
Note that the percentage of mitotic cells present in HeLa mSPD2 BAC-containing cells is reduced compared with that observed in WT cells.
2400  www.pnas.orgcgidoi10.1073pnas.0409861102 Kittler et al.
schemes have also begun providing insights into the localization
of the mammalian proteome (35). In these studies, cDNA
constructs, whose expression is typically driven by viral promot-
ers, are used, and, as a consequence, the GFP-tagged genes are
typically expressed at nonphysiological levels, which can lead to
phenotypes and mislocalization (36–38). Furthermore, the ex-
pression of cDNAs precludes the visualization of alternatively
spliced variants, which may differ in their subcellular localiza-
tion. However, for the reasons mentioned earlier, the use of
modified BACs may overcome these limitations (Fig. 4a).
To test whether BAC-GFP tagging can be combined with
cross-species RNAi rescue and thereby allow functional expres-
sion of the tagged protein in the absence of the endogenous
protein, we inserted a GFP tag at the C terminus of the mouse
homologue of the C. elegans SPD2 protein (39). Consistent
with the localization pattern of SPD2 in C. elegans and its role in
spindle assembly in the early embryo (39, 40), the hu-
man homologue of SPD2 (hSPD2) also localizes to the
centrosome (41).
As was observed for the mSNW1 clones, most mSPD2 clones
expressed the mouse transgene at equivalent levels to that of the
endogenous human gene, and transfection of human-specific
siRNA resulted in predominant silencing of the human transcript
(data not shown). Immunofluorescence analysis of mSPD2
transgenic lines revealed that SPD2-GFP fluorescence was re-
stricted to the mitotic spindle poles, suggesting that the tagging
does not interfere with the subcellular localization of SPD2 (Fig.
4b). We next wanted to determine whether the murine SPD2-
GFP BACwas able to complement functionally the human SPD2
gene. Consistent with its role in spindle assembly in C. elegans,
the depletion of SPD2 in HeLa cells by RNAi leads to an
increase in the mitotic index of cells from 5% in control
transfected cells (data not shown) to 25% in cells treated with
siRNA against SPD2 (Fig. 4c). In contrast, in cells expressing the
mSPD2-GFP transgene, the mitotic index dropped considerably
toward WT levels (Fig. 4c). These results demonstrate that
tagging by BAC recombineering can be combined with RNAi to
mimic homologous recombination in mammalian tissue culture
cells. In particular the ability to introduce tagged transgenes on
their own promoter, and to remove the endogenous gene
function, heralds the era of mammalian tissue culture cell
genetics.
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